HLVX HilleVax, Inc.Stock Price & Overview
$13.04-0.55 (-4.05%)4:00 PM 09/22/23
NASDAQ | $USD | Post-Market: $13.04 4:52 PM
Charts
FFO (FWD)
PE
Div Rate (TTM)
Yield (TTM)
Short Interest
Market Cap
Volume
Prev. Close
Quant Ranking
Ratings Summary
| Now | 6M ago | |
|---|---|---|
SA Analysts | Not CoveredRating: Not Covered | |
Wall Street | Not CoveredRating: Not Covered | |
Quant | Not CoveredRating: Not Covered | |
Ratings Summary
SA Analysts
Wall Street
Quant
| Now | 3M ago | 6M ago | |
|---|---|---|---|
Valuation | -Rating: Not Covered | ||
Growth | -Rating: Not Covered | ||
Profitability | -Rating: Not Covered | ||
Momentum | -Rating: Not Covered | ||
Revisions | -Rating: Not Covered | ||
See HLVX ratings with Premium.
Company Profile
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus and related illness. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.
Address
- 75 State Street
- Suite 100- #9995
- Boston, MA, 02109
- United States
Phone Number
617 213 5054
Website